Characterization of cardiac oxidative stress levels in patients with atrial fibrillation

Heart and Vessels

Volumn 31, Issue 1, 2016, Pages 80-87

  Okada, Ayako ^a   Kashima, Yuichiro ^a   Tomita, Takeshi ^a   Takeuchi, Takahiro ^a   Aizawa, Kazunori ^a   Takahashi, Masafumi ^b   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Ablation; Atrial fibrillation; Brain natriuretic peptide; Oxidative stress

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIACRON REACTIVE OXYGEN METABOLITE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIAC OXIDATIVE STRESS; CARDIOVASCULAR PARAMETERS; CATHETER ABLATION; CONTROLLED STUDY; CORONARY SINUS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; HEART LEFT ATRIUM; HEART LEFT ATRIUM DIAMETER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICULAR DIASTOLIC DIAMETER; HEART RIGHT ATRIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PAROXYSMAL ATRIAL FIBRILLATION; PATHOPHYSIOLOGY; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; AGED; ATRIAL FIBRILLATION; BLOOD; ECHOCARDIOGRAPHY;

AGED; ATRIAL FIBRILLATION; BIOMARKERS; CATHETER ABLATION; CORONARY SINUS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84952988517     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0582-8     Document Type: Article

References (24)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society (2006) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257–354
2. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219–226
3. Yang KC, Dudley SC Jr (2013) Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. Circulation 128:1724–1726
4. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, Weiss JN, Cai H (2013) Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 62:72–79
5. Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028
6. Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi:10.1007/s00380-013-0400-8
7. Sovari AA, Dudley SC (2012) Antioxidant therapy for atrial fibrillation: lost in translation? Heart 98:1615–1616
8. Van Wagoner DR (2008) Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 52:306–313
9. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR (2001) Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89:E32–E38
10. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S (2004) Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110:2313–2319
11. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr (2007) Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53:1652–1657
12. Shimano M, Shibata R, Inden Y, Yoshida N, Uchikawa T, Tsuji Y, Murohara T (2009) Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 6:935–940
13. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174–180
14. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B (2008) Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51:68–74
15. Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274
16. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159–163
17. Gould PA, Gula LJ, Bhayana V, Subbiah RN, Bentley C, Yee R, Klein GJ, Krahn AD, Skanes AC (2010) Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation. Circ Arrhythm Electrophysiol 3:18–23
18. Kurosaki K, Tada H, Hashimoto T, Ito S, Miyaji K, Naito S, Oshima S, Taniguchi K (2007) Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. Circ J 71:313–320
19. Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127
20. Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535
21. von Lüdinghausen M, Ohmachi N, Besch S, Mettenleiter A (1995) Atrial veins of the human heart. Clin Anat 8:169–189
22. Kim BJ, Hwang SJ, Sung KC, Kim BS, Kang JH, Lee MH, Park JR (2007) Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. Int J Cardiol 118:145–150
23. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96
24. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Bergler-Klein J, Binder T, Wojta J, Gössinger HD (2012) Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 101:217–225